Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

MIRM

Mirum Pharmaceuticals Inc

Feb 11 • 04:00PM ET

99.88

-1.03 -1.02 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX GILD AKRO ENTA MDGL PTCT NBIX VKTX DVAX GLMD

| Held by: XBI VTI IWM VXF IWO IBB SCHA VTWO VHT FESM

Index	RUT	P/E	-	EPS (ttm)	-0.86	Insider Own	12.13%	Shs Outstand	51.31M	Perf Week	-3.92%
Market Cap	5.16B	Forward P/E	-	EPS next Y	-0.06	Insider Trans	-2.17%	Shs Float	45.41M	Perf Month	11.60%
Enterprise Value	5.11B	PEG	-	EPS next Q	0.04	Inst Own	99.11%	Short Float	17.17%	Perf Quarter	43.28%
Income	-41.42M	P/S	10.94	EPS this Y	86.38%	Inst Trans	6.77%	Short Ratio	10.27	Perf Half Y	54.33%
Sales	471.79M	P/B	17.55	EPS next Y	77.38%	ROA	-5.70%	Short Interest	7.80M	Perf YTD	26.45%
Book/sh	5.69	P/C	13.75	EPS next 5Y	-	ROE	-15.81%	52W High	105.74 -5.54%	Perf Year	99.12%
Cash/sh	7.27	P/FCF	116.48	EPS past 3/5Y	12.58% 4.14%	ROIC	-6.80%	52W Low	36.88 170.82%	Perf 3Y	321.97%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	160.13% -	Gross Margin	79.85%	Volatility	3.61% 3.89%	Perf 5Y	386.51%
Dividend TTM	-	EV/Sales	10.82	EPS Y/Y TTM	58.63%	Oper. Margin	-8.86%	ATR (14)	3.67	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.16	Sales Y/Y TTM	53.66%	Profit Margin	-8.78%	RSI (14)	61.92	Recom	1.09
Dividend Gr. 3/5Y	- -	Current Ratio	3.31	EPS Q/Q	117.12%	SMA20	1.61%	Beta	0.51	Target Price	114.70
Payout	-	Debt/Eq	1.09	Sales Q/Q	47.17%	SMA50	18.54%	Rel Volume	0.69	Prev Close	100.91
Employees	322	LT Debt/Eq	1.08	Earnings	Nov 04 AMC	SMA200	49.98%	Avg Volume	759.22K	Price	99.88
IPO	Jul 18, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	135.66% 1.93%	Trades		Volume	520,900	Change	-1.02%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-24-25	Initiated	TD Cowen	Buy	$95
Aug-11-25	Resumed	Stifel	Buy	$89
May-19-25	Resumed	H.C. Wainwright	Buy	$73
Apr-17-24	Initiated	Stifel	Buy	$48
Dec-18-23	Reiterated	H.C. Wainwright	Buy	$60 → $58
Nov-20-23	Resumed	JP Morgan	Overweight	$37
Nov-13-23	Initiated	Morgan Stanley	Overweight	$60
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Oct-17-23	Resumed	Evercore ISI	Outperform	$62
Sep-20-23	Initiated	JMP Securities	Mkt Outperform	$70
Sep-01-22	Initiated	Citigroup	Buy	$38
Sep-20-21	Initiated	JP Morgan	Overweight	$30
Aug-07-20	Upgrade	Raymond James	Outperform → Strong Buy	$28 → $48
Aug-03-20	Initiated	H.C. Wainwright	Buy	$52
Jul-31-20	Initiated	Piper Sandler	Overweight	$77
Jun-25-20	Initiated	Robert W. Baird	Outperform	$30
Aug-12-19	Initiated	ROTH Capital	Buy	$33
Aug-12-19	Initiated	Raymond James	Outperform	$28
Aug-12-19	Initiated	Guggenheim	Buy	$18
Aug-12-19	Initiated	Evercore ISI	Outperform

Show Previous Ratings

Feb-10-26 10:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-05-26 08:51AM	Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (Business Wire) -5.51%
08:00AM	Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) (Business Wire)
Feb-03-26 02:10AM	Mirum doubles down on diversified rare disease strategy (Pharma Voice)
Jan-31-26 03:22PM	Is Mirum Pharmaceuticals on a Strong Path to Profitability? (Motley Fool)
08:15AM	Loading…
08:15AM	Insiders Are Still Scooping Up Under Armour and WR Berkley Shares (24/7 Wall St.)
Jan-29-26 02:27PM	H.C. Wainwright Raises PT on Mirum Pharmaceuticals For the Second Time In a Span of Two Weeks, Here is Why? (Insider Monkey)
Jan-27-26 06:33AM	Mirum acquires Bluejay Therapeutics to expand rare liver disease pipeline (Pharmaceutical Technology)
03:15AM	Is Mirum Pharmaceuticals About to Soar in 2026? (Motley Fool)
Jan-26-26 08:00AM	Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease (Business Wire)
Jan-22-26 09:52PM	Baird Updates Mirum Pharmaceuticals (MIRM) Valuation Following Beat-and-Raise Earnings Results (Insider Monkey)
Jan-20-26 09:38AM	CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy? (Zacks)
Jan-16-26 11:08AM	Mirum Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
Jan-13-26 05:04AM	3 Top Growth Stocks to Buy in the First Half of 2026 (Motley Fool)
Jan-12-26 05:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Loading…
08:30AM	Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum (Business Wire)
Jan-09-26 11:55AM	Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals (Business Wire) +6.09%
Jan-07-26 04:01PM	Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) +7.22%
Jan-06-26 08:03AM	Should You Invest in Mirum Pharmaceuticals (MIRM)? (Insider Monkey)
Jan-04-26 04:05AM	5 Predictions for the Stock Market in 2026 -- and Which Stocks Will Soar the Most If They're Right (Motley Fool)
Dec-30-25 03:07AM	Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now (Motley Fool)
Dec-23-25 01:52PM	This Biotech Name Outperforms 93% Of Stocks, And It's In A Buy Zone (Investor's Business Daily)
Dec-19-25 08:30AM	Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX (Business Wire) +10.61%
Dec-18-25 10:41AM	Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026? (Zacks)
Dec-11-25 07:44AM	Morgan Stanley Raises Mirum (MIRM) PT to $95 on Strategic Bluejay Acquisition, Brelovitug Pipeline Addition (Insider Monkey)
Dec-09-25 09:45AM	Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald (TipRanks)
09:42AM	Mirum to buy Bluejay for up to $820m in rare liver disease push (Pharmaceutical Technology)
Dec-08-25 08:31AM	Mirum gains a hepatitis D drug in $620M buyout of startup Bluejay (BioPharma Dive)
08:00AM	Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease (Business Wire)
Dec-04-25 11:30AM	Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue? (Zacks)
06:30AM	Loading…
Dec-03-25 06:30AM	Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026 (Motley Fool)
Dec-02-25 10:15AM	MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study (Zacks)
Dec-01-25 08:10AM	Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome (Business Wire)
Nov-28-25 10:07AM	Biotechs Are On A Big Run, And Two Stocks Have Buy Points (Investor's Business Daily)
Nov-25-25 04:02PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Nov-10-25 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-25 08:10AM	Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI and Volixibat Clinical Programs at AASLDs The Liver Meeting (Business Wire)
Nov-05-25 11:27AM	MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened (Zacks)
12:04AM	Mirum Pharmaceuticals Inc (MIRM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-04-25 05:10PM	Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Nov-03-25 04:05PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Oct-29-25 10:00AM	Techne (TECH) Reports Next Week: What to Know Ahead of the Release (Zacks)
Oct-28-25 04:02PM	Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 (Business Wire)
Oct-14-25 10:56AM	Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings? (Zacks)
Oct-10-25 07:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-23-25 10:44AM	CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick? (Zacks)
Sep-10-25 06:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-08-25 08:00AM	Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study (Business Wire)
Aug-27-25 04:02PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-11-25 05:31PM	IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies \| DelveInsight (PR Newswire) +9.84%
09:33AM	Arm initiated, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Aug-07-25 11:20AM	MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View (Zacks) +12.04%
Aug-06-25 05:55PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Jul-31-25 07:40AM	Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-30-25 04:01PM	Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 (Business Wire)
10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-17-25 10:02AM	Mirum Gains 35% in 3 Months: How Should You Play the Stock? (Zacks)
Jul-10-25 06:15PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-24-25 12:15PM	EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch (Zacks)
Jun-17-25 12:36PM	Liver Drug Stock Rockets 236% Amid FDA Approval As Sales Accelerate; Funds Load Up (Investor's Business Daily)
Jun-13-25 01:57PM	CoreWeave Leads Four Stocks Near Buy Points; One Is Also An Nvidia Partner (Investor's Business Daily)
Jun-11-25 11:30AM	Why Is Editas (EDIT) Up 40% Since Last Earnings Report? (Zacks)
Jun-10-25 08:40PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-06-25 11:31AM	Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report? (Zacks)
Jun-03-25 11:41AM	FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch (Zacks)
May-19-25 08:30AM	Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer (Business Wire)
May-14-25 04:05PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
May-09-25 06:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Volixibat Data from Mirums VANTAGE PBC Study Showcased at EASL (Business Wire)
May-08-25 12:13PM	Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised (Zacks) +9.75%
07:08AM	Q1 2025 Mirum Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:29AM	Mirum Pharmaceuticals Inc (MIRM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
May-07-25 09:17PM	Mirum pharmaceuticals raises 2025 revenue guidance to $435M-$450M driven by robust growth (Seeking Alpha)
09:17PM	Mirum Pharmaceuticals, Inc. (MIRM) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
May-06-25 05:05PM	Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -7.13%
May-05-25 10:00AM	Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
May-04-25 06:45PM	Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities (Seeking Alpha)
Apr-30-25 08:30AM	Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 (Business Wire)
Apr-28-25 08:30AM	Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses (Business Wire)
Apr-25-25 09:40AM	Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? (Zacks)
Apr-14-25 08:30AM	Mirums LIVMARLI Now FDA Approved in Tablet Formulation (Business Wire)
Apr-10-25 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.67%
Apr-03-25 09:34AM	Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? (Zacks)
Mar-28-25 11:30AM	Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-27-25 08:30AM	LIVMARLI Now Approved in Japan for ALGS and PFIC (Business Wire)
Mar-24-25 05:17PM	Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call (SeekingAlpha)
12:24PM	Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like (SeekingAlpha)
Mar-21-25 12:37PM	Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe (Zacks)
Mar-10-25 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 10:56AM	Q4 2024 Mirum Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -7.02%
02:22AM	Mirum Pharmaceuticals Inc (MIRM) Q4 2024 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com)
Feb-26-25 05:15PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update (Business Wire)
11:48AM	Mirum Pharmaceuticals (MIRM): Among the Best Performing Mid Cap Stocks to Buy According to Analysts (Insider Monkey)
09:55AM	Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know (Zacks)
Feb-24-25 08:30AM	Mirums CTEXLI (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX) (Business Wire)

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Radovich Peter	PRESIDENT AND COO	Feb 02 '26	Sale	103.30	2,631	271,792	20,655	Feb 03 09:45 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Feb 02 '26	Sale	103.30	9,108	940,888	160,294	Feb 03 09:45 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Feb 02 '26	Sale	103.30	968	99,998	4,503	Feb 03 09:45 PM
Jolanda Howe	Officer	Feb 02 '26	Proposed Sale	103.80	968	100,478		Feb 02 08:29 PM
Peter Radovich	Officer	Feb 02 '26	Proposed Sale	103.80	2,631	273,098		Feb 02 08:25 PM
Christopher Peetz	Officer	Feb 02 '26	Proposed Sale	103.80	9,108	945,410		Feb 02 08:21 PM
Jolanda Howe	Officer	Jan 26 '26	Proposed Sale	96.92	842	81,607		Jan 28 06:47 PM
ERIC BJERKHOLT	Officer	Jan 26 '26	Proposed Sale	96.92	1,053	102,057		Jan 28 06:44 PM
Peter Radovich	Officer	Jan 26 '26	Proposed Sale	96.92	3,143	304,620		Jan 28 06:43 PM
Christopher Peetz	Officer	Jan 26 '26	Proposed Sale	96.92	6,831	662,061		Jan 28 06:40 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jan 26 '26	Sale	96.19	1,053	101,290	43,741	Jan 27 04:30 PM
Radovich Peter	PRESIDENT AND COO	Jan 26 '26	Sale	96.19	3,143	302,331	23,286	Jan 27 04:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 26 '26	Sale	96.19	842	80,994	3,700	Jan 27 04:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 26 '26	Sale	96.19	6,831	657,088	169,402	Jan 27 04:30 PM
Heron Patrick J	Director	Jan 23 '26	Buy	68.48	131,425	8,999,984	459,010	Jan 27 04:14 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 22 '26	Sale	93.33	926	86,419	3,042	Jan 23 05:30 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Jan 22 '26	Sale	93.33	1,822	170,039	12,817	Jan 23 05:30 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jan 22 '26	Sale	93.33	1,421	132,615	42,127	Jan 23 05:30 PM
Radovich Peter	PRESIDENT AND COO	Jan 22 '26	Sale	93.33	2,382	222,301	20,679	Jan 23 05:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 22 '26	Sale	93.33	7,098	662,422	163,733	Jan 23 05:30 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Jan 20 '26	Sale	90.27	6,911	623,853	11,305	Jan 21 04:05 PM
Ramasastry Saira	Director	Jan 15 '26	Option Exercise	23.51	2,000	47,020	2,000	Jan 16 04:05 PM
Ramasastry Saira	Director	Jan 15 '26	Sale	90.99	2,000	181,980	0	Jan 16 04:05 PM
SAIRA RAMASASTRY	Director	Jan 15 '26	Proposed Sale	90.99	2,000	181,980		Jan 15 04:02 PM
Ramasastry Saira	Director	Dec 22 '25	Option Exercise	23.51	5,000	117,550	5,000	Dec 23 06:52 PM
Ramasastry Saira	Director	Dec 22 '25	Sale	80.00	5,000	400,000	0	Dec 23 06:52 PM
GREY MICHAEL G	Director	Dec 19 '25	Option Exercise	2.94	50,000	146,800	50,000	Dec 23 06:50 PM
GREY MICHAEL G	Director	Dec 19 '25	Sale	78.00	50,000	3,900,000	0	Dec 23 06:50 PM
SAIRA RAMASASTRY	Director	Dec 22 '25	Proposed Sale	80.00	5,000	400,000		Dec 22 04:03 PM
Ramasastry Saira	Director	Dec 18 '25	Option Exercise	23.51	2,000	47,020	2,000	Dec 19 04:15 PM
Ramasastry Saira	Director	Dec 18 '25	Sale	69.73	2,000	139,460	0	Dec 19 04:15 PM
MICHAEL GREY	Director	Dec 19 '25	Proposed Sale	78.00	50,000	3,900,000		Dec 19 04:05 PM
SAIRA RAMASASTRY	Director	Dec 18 '25	Proposed Sale	69.73	2,000	139,460		Dec 18 04:09 PM
GREY MICHAEL G	Director	Dec 01 '25	Option Exercise	2.94	50,000	146,800	50,000	Dec 02 04:04 PM
GREY MICHAEL G	Director	Dec 01 '25	Sale	74.00	50,000	3,700,000	0	Dec 02 04:04 PM
MICHAEL GREY	Director	Dec 01 '25	Proposed Sale	74.00	50,000	3,700,000		Dec 01 04:07 PM
GREY MICHAEL G	Director	Nov 21 '25	Option Exercise	2.94	50,000	146,800	50,000	Nov 25 04:10 PM
GREY MICHAEL G	Director	Nov 21 '25	Sale	70.00	50,000	3,500,000	0	Nov 25 04:10 PM
MICHAEL GREY	Director	Nov 21 '25	Proposed Sale	70.00	50,000	3,500,000		Nov 21 04:09 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Nov 18 '25	Option Exercise	19.24	19,133	368,119	158,034	Nov 20 04:21 PM
Brege Laura	Director	Sep 11 '25	Option Exercise	15.00	17,000	255,000	32,703	Sep 12 08:00 PM
Brege Laura	Director	Sep 11 '25	Sale	74.40	17,000	1,264,868	15,703	Sep 12 08:00 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Sep 12 '25	Sale	76.01	9,578	728,024	39,945	Sep 12 08:00 PM
LAURA BREGE	Director	Sep 11 '25	Proposed Sale	74.41	17,000	1,264,917		Sep 11 04:04 PM
Ramasastry Saira	Director	Sep 08 '25	Option Exercise	23.51	17,000	399,670	17,000	Sep 10 05:50 PM
SAIRA RAMASASTRY	Director	Sep 08 '25	Proposed Sale	77.04	17,000	1,309,716		Sep 08 04:06 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Aug 12 '25	Option Exercise	26.49	2,954	78,251	31,190	Aug 12 08:00 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 11 '25	Option Exercise	2.94	40,000	117,440	178,641	Aug 12 07:57 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 11 '25	Sale	62.00	40,000	2,480,000	138,641	Aug 12 07:57 PM
CHRISTOPHER PEETZ	Officer	Aug 11 '25	Proposed Sale	62.00	40,000	2,480,000		Aug 11 04:06 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 07 '25	Option Exercise	6.27	10,000	62,700	12,426	Aug 08 04:50 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 07 '25	Sale	58.00	10,000	580,000	2,426	Aug 08 04:50 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 07 '25	Option Exercise	2.94	40,000	117,440	178,641	Aug 08 04:49 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 07 '25	Sale	55.25	40,000	2,210,040	138,641	Aug 08 04:49 PM
JOLANDA MARIE HOWE	Officer	Aug 07 '25	Proposed Sale	58.00	10,000	580,000		Aug 07 04:26 PM
CHRISTOPHER PEETZ	Officer	Aug 07 '25	Proposed Sale	55.25	40,000	2,210,040		Aug 07 04:25 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 02 '25	Sale	48.25	564	27,213	2,903	Jul 03 06:48 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 03 '25	Sale	49.08	477	23,411	2,426	Jul 03 06:48 PM
JOLANDA MARIE HOWE	Officer	Jul 03 '25	Proposed Sale	49.08	477	23,411		Jul 03 01:13 PM
Fairey William	Director	Jun 11 '25	Sale	48.42	3,203	155,091	2,500	Jun 13 04:18 PM
WILLIAM C FAIREY	Director	Jun 11 '25	Proposed Sale	48.42	3,203	155,091		Jun 11 04:05 PM
Ramasastry Saira	Director	Jun 03 '25	Option Exercise	14.12	2,500	35,300	2,500	Jun 04 04:11 PM
Ramasastry Saira	Director	Jun 02 '25	Sale	46.20	5,703	263,492	0	Jun 04 04:11 PM
Ramasastry Saira	Director	Jun 03 '25	Sale	45.74	2,500	114,352	0	Jun 04 04:11 PM
SAIRA RAMASASTRY	Director	Jun 03 '25	Proposed Sale	45.74	2,500	114,352		Jun 03 05:07 PM
SAIRA RAMASASTRY	Director	Jun 02 '25	Proposed Sale	46.20	5,703	263,492		Jun 02 06:43 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 18 '25	Sale	44.45	2,415	107,343	2,426	Mar 19 05:40 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 17 '25	Option Exercise	2.94	52,900	155,526	59,547	Mar 18 09:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 17 '25	Sale	44.35	57,606	2,554,763	4,841	Mar 18 09:30 PM
Radovich Peter	PRESIDENT AND COO	Mar 17 '25	Sale	44.21	7,879	348,364	18,672	Mar 18 09:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 17 '25	Sale	44.21	27,279	1,206,122	138,641	Mar 18 09:30 PM
Heron Patrick J	Director	Mar 14 '25	Buy	44.11	528	23,291	168,651	Mar 18 05:04 PM
Heron Patrick J	Director	Mar 17 '25	Buy	43.93	21	923	168,672	Mar 18 05:04 PM
JOLANDA MARIE HOWE	Officer	Mar 18 '25	Proposed Sale	44.45	2,415	107,343		Mar 18 04:12 PM
JOLANDA MARIE HOWE	Officer	Mar 17 '25	Proposed Sale	44.36	54,706	2,426,540		Mar 17 04:21 PM
Heron Patrick J	Director	Mar 10 '25	Buy	42.97	1,335	57,363	167,160	Mar 12 04:51 PM
Heron Patrick J	Director	Mar 11 '25	Buy	43.77	963	42,155	168,123	Mar 12 04:51 PM
Heron Patrick J	Director	Mar 06 '25	Buy	43.89	1,335	58,597	165,245	Mar 10 05:12 PM
Heron Patrick J	Director	Mar 07 '25	Buy	43.21	580	25,064	165,825	Mar 10 05:12 PM
Heron Patrick J	Director	Mar 04 '25	Buy	45.57	1,335	60,830	163,643	Mar 06 05:30 PM
Heron Patrick J	Director	Mar 05 '25	Buy	44.55	267	11,894	163,910	Mar 06 05:30 PM
Radovich Peter	PRESIDENT AND COO	Mar 04 '25	Sale	45.58	14,850	676,928	12,111	Mar 05 04:28 PM
Radovich Peter	Officer	Mar 04 '25	Proposed Sale	45.52	14,850	675,956		Mar 04 04:43 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 03 '25	Option Exercise	2.94	40,000	117,440	155,920	Mar 04 04:26 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 03 '25	Sale	46.91	40,000	1,876,353	115,920	Mar 04 04:26 PM
CHRISTOPHER PEETZ	Officer	Mar 03 '25	Proposed Sale	46.91	40,000	1,876,280		Mar 03 04:49 PM

Open in Screener

ACAD

Acadia Pharmaceuticals Inc

Feb 11 • 04:00PM ET

22.47

-0.23 -1.01 %

Healthcare • Biotechnology • USA • NASD

ACAD Acadia Pharmaceuticals Inc daily Stock Chart

Peers: NBIX BIIB VRTX INCY BMRN ALNY IONS REGN GILD AMGN

| Held by: IJR VTI VB XBI IWM FBT VBK VXF IBB SPSM

Index	RUT	P/E	14.46	EPS (ttm)	1.55	Insider Own	1.08%	Shs Outstand	169.15M	Perf Week	-7.26%
Market Cap	3.80B	Forward P/E	31.44	EPS next Y	0.71	Insider Trans	-4.11%	Shs Float	167.35M	Perf Month	-15.49%
Enterprise Value	3.01B	PEG	-	EPS next Q	0.13	Inst Own	100.08%	Short Float	5.57%	Perf Quarter	1.22%
Income	261.17M	P/S	3.63	EPS this Y	-39.88%	Inst Trans	-0.51%	Short Ratio	6.62	Perf Half Y	-11.71%
Sales	1.05B	P/B	4.14	EPS next Y	-12.58%	ROA	22.64%	Short Interest	9.31M	Perf YTD	-15.87%
Book/sh	5.42	P/C	4.49	EPS next 5Y	-7.12%	ROE	34.95%	52W High	28.35 -20.74%	Perf Year	21.53%
Cash/sh	5.01	P/FCF	19.22	EPS past 3/5Y	- -	ROIC	27.20%	52W Low	13.40 67.69%	Perf 3Y	18.45%
Dividend Est.	-	EV/EBITDA	27.75	Sales past 3/5Y	25.54% 23.08%	Gross Margin	91.92%	Volatility	3.37% 3.73%	Perf 5Y	-56.15%
Dividend TTM	-	EV/Sales	2.87	EPS Y/Y TTM	100.80%	Oper. Margin	9.02%	ATR (14)	0.90	Perf 10Y	28.03%
Dividend Ex-Date	-	Quick Ratio	2.94	Sales Y/Y TTM	12.69%	Profit Margin	24.94%	RSI (14)	28.37	Recom	1.85
Dividend Gr. 3/5Y	- -	Current Ratio	3.02	EPS Q/Q	113.29%	SMA20	-11.33%	Beta	0.67	Target Price	31.21
Payout	0.00%	Debt/Eq	0.06	Sales Q/Q	11.27%	SMA50	-14.34%	Rel Volume	0.69	Prev Close	22.70
Employees	654	LT Debt/Eq	0.05	Earnings	Feb 25 AMC	SMA200	-3.29%	Avg Volume	1.41M	Price	22.47
IPO	May 27, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	142.91% 0.76%	Trades		Volume	977,478	Change	-1.01%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-21-25	Initiated	Citigroup	Buy	$33
May-21-25	Upgrade	Deutsche Bank	Hold → Buy	$35
Feb-11-25	Initiated	Deutsche Bank	Hold	$22
Jan-03-25	Downgrade	Guggenheim	Buy → Neutral	$23 → $20
Oct-10-24	Resumed	Raymond James	Mkt Perform
Aug-07-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$28 → $20
Jun-27-24	Initiated	BMO Capital Markets	Outperform	$31
Mar-12-24	Reiterated	Needham	Buy	$36 → $32
Mar-12-24	Downgrade	Mizuho	Buy → Neutral	$39 → $25
Jan-30-24	Initiated	Robert W. Baird	Outperform	$40
Jan-24-24	Upgrade	Needham	Hold → Buy	$37
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$31 → $40
Dec-14-23	Downgrade	Deutsche Bank	Buy → Hold	$25
Dec-13-23	Initiated	Citigroup	Buy	$38
Dec-12-23	Initiated	Deutsche Bank	Buy	$25
Nov-06-23	Upgrade	Mizuho	Neutral → Buy	$20 → $35
Oct-17-23	Initiated	UBS	Buy	$33
Oct-10-23	Upgrade	JP Morgan	Neutral → Overweight	$29 → $32
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy	$22
Nov-04-22	Downgrade	Goldman	Neutral → Sell	$15 → $12

Show Previous Ratings

Feb-04-26 04:05PM	Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 (Business Wire)
Feb-03-26 12:44PM	EU Panel Rejects Acadia Pharmaceuticals Rett Syndrome Drug (Benzinga) -5.24%
10:00AM	5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates (Zacks)
07:52AM	Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU (Zacks)
05:11AM	FDA launches PreCheck program; AstraZeneca, Acadia drugs set back (BioPharma Dive)
04:05PM	Loading…
Feb-02-26 04:05PM	Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union (Business Wire)
12:10PM	Why Acadia (ACAD) is Poised to Beat Earnings Estimates Again (Zacks)
Jan-28-26 11:40AM	FTRE or ACAD: Which Is the Better Value Stock Right Now? (Zacks)
Jan-26-26 10:15AM	Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026? (Zacks)
Jan-13-26 02:06PM	ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Maps Key Remlifansirin Readouts at JPM Conf (MarketBeat)
09:00AM	Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-12-26 04:01PM	Acadia Pharmaceuticals Focuses on Next-Gen Neuroscience (Bloomberg)
11:40AM	FTRE vs. ACAD: Which Stock Is the Better Value Option? (Zacks)
Dec-22-25 09:50AM	Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock (Zacks)
Dec-18-25 04:05PM	Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 (Business Wire)
08:00AM	Loading…
Dec-12-25 08:00AM	Acadia Pharmaceuticals Announces FDA Approval of DAYBUE STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome (Business Wire)
Dec-11-25 04:27PM	Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win (Investor's Business Daily)
Dec-10-25 11:30AM	Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report? (Zacks)
Dec-05-25 11:30AM	Why Is Acadia (ACAD) Up 22.6% Since Last Earnings Report? (Zacks)
Dec-03-25 09:17AM	Acadia to pivot to Alzheimers psychosis pipeline, accd to Wall Street analysts (Investing.com)
Nov-28-25 09:50AM	Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock (Zacks)
Nov-20-25 04:05PM	Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference (Business Wire)
Nov-12-25 09:50AM	Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-07-25 10:11AM	Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
09:56AM	Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble (Zacks)
Nov-06-25 11:23AM	ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth (Zacks)
10:43AM	Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
09:24AM	RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y (Zacks)
12:00AM	ACADIA Pharmaceuticals Inc (ACAD) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Nov-05-25 05:20PM	Acadia Pharmaceuticals (ACAD) Q3 Earnings and Revenues Top Estimates (Zacks)
04:18PM	Loading…
04:18PM	Acadia: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview (Business Wire)
12:04PM	Waters Q3 Earnings Surpass Estimates, Revenue Increase Y/Y (Zacks)
Oct-29-25 10:00AM	Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-28-25 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
12:00PM	Acadia (ACAD) Moves to Buy: Rationale Behind the Upgrade (Zacks)
09:55AM	Does Acadia (ACAD) Have the Potential to Rally 27.66% as Wall Street Analysts Expect? (Zacks)
09:40AM	Is HCA HEALTHCARE (HCA) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-22-25 03:41PM	Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-21-25 09:20AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Oct-15-25 04:05PM	Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025 (Business Wire) +6.78% -5.15%
Oct-09-25 11:40AM	QGEN vs. ACAD: Which Stock Is the Better Value Option? (Zacks)
Oct-02-25 09:04AM	Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders (Business Wire)
Sep-30-25 09:45AM	Can Auvelity Drive Axsome's Growth Through the Rest of 2025? (Zacks)
Sep-25-25 10:50AM	ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure (Zacks)
Sep-24-25 04:20PM	Acadia Pharma Tumbles On Failed Genetic Disease Drug; Soleno Surges (Investor's Business Daily) -9.92%
09:32AM	Acadia Pharma Tumbles On Failed Appetite Suppressant; Soleno Surges (Investor's Business Daily)
09:27AM	Lithium Americas, Oracle, Acadia Pharma: Trending Tickers (Yahoo Finance Video)
07:28AM	Acadia to scrap Prader-Willi drug after study setback (BioPharma Dive)
07:00AM	Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint (Business Wire)
02:12AM	ACADIA Pharmaceuticals (ACAD) Announces Interim Results From LOTUS study on DAYBUE (Insider Monkey)
Sep-12-25 04:05PM	Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology (Business Wire)
Sep-11-25 11:13AM	ACADIA Pharmaceuticals Inc. (ACAD) Nears Key Phase 3 Readout in Prader-Willi Syndrome (Insider Monkey)
Sep-08-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-29-25 12:27PM	Axsome Shares Up 20% in a Month: How Should You Play the Stock? (Zacks)
04:53AM	ACADIA Pharmaceuticals Inc. (ACAD) Nears Phase 3 Readout in Prader-Willi Syndrome Trial (Insider Monkey)
Aug-26-25 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
Aug-25-25 04:05PM	Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer (Business Wire)
Aug-21-25 09:49AM	JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug (Zacks)
Aug-11-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-07-25 10:04AM	Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth (Zacks)
Aug-06-25 05:15PM	Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates (Zacks)
04:19PM	Acadia: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview (Business Wire)
Aug-05-25 06:00PM	Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference (Business Wire)
09:32AM	Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards? (Zacks)
Aug-04-25 04:05PM	Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer (Business Wire)
12:23PM	Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards? (Zacks)
11:07AM	Sarepta to Report Q2 Earnings: What's in Store for the Stock? (Zacks)
Aug-01-25 11:40AM	GMAB vs. ACAD: Which Stock Is the Better Value Option? (Zacks)
Jul-30-25 10:00AM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-23-25 04:05PM	Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025 (Business Wire)
Jul-10-25 08:00AM	Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity (Investor's Business Daily)
Jul-04-25 11:40AM	KMDA or ACAD: Which Is the Better Value Stock Right Now? (Zacks)
Jul-03-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-26-25 08:23AM	Acadias very bullish sales forecast restores some confidence on Wall Street (BioPharma Dive)
Jun-25-25 08:00AM	Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers (Business Wire)
Jun-24-25 01:05PM	Acadia Pharmaceuticals price target raised to $38 from $26 at RBC Capital (TipRanks)
Jun-18-25 11:40AM	KMDA vs. ACAD: Which Stock Is the Better Value Option? (Zacks)
Jun-17-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-11-25 07:40PM	US Appeals Court Confirms Patent Validity of Acadia's Parkinson's Medication (Insider Monkey)
Jun-09-25 04:01PM	U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID (pimavanserin) Composition of Matter Patent (Business Wire)
Jun-06-25 11:31AM	Why Is Acadia (ACAD) Up 26.1% Since Last Earnings Report? (Zacks)
Jun-05-25 09:05AM	Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025 (Business Wire)
May-29-25 04:05PM	Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (Business Wire)
May-27-25 04:05PM	Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise (Business Wire)
May-20-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
12:52PM	Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday (Insider Monkey)
10:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
May-19-25 03:07PM	ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93 (Investor's Business Daily)
11:40AM	GSK or ACAD: Which Is the Better Value Stock Right Now? (Zacks)
09:32AM	ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent (Zacks)
May-17-25 01:36PM	Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer (TipRanks)
01:36PM	Acadia Nuplazid patent ruling removes key overhang, says BMO Capital (TipRanks)
May-16-25 01:43PM	Delaware District Court Rules in Favor of Acadia in NUPLAZID (pimavanserin) Formulation Patent Litigation (Business Wire) +26.48%
May-09-25 06:26PM	Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised) (Zacks)
May-08-25 10:40AM	Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth (Zacks) +14.31%
08:03AM	Q1 2025 ACADIA Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:28AM	ACADIA Pharmaceuticals Inc (ACAD) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rhodes Jennifer J	EVP, CHIEF LEGAL OFFICER, SEC	Feb 06 '26	Option Exercise	0.00	12,944	0	14,559	Feb 10 06:00 PM
Rhodes Jennifer J	EVP, CHIEF LEGAL OFFICER, SEC	Feb 09 '26	Sale	23.38	6,950	162,491	7,609	Feb 10 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Nov 18 '25	Sale	23.69	10,262	243,114	53,338	Nov 19 06:00 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Nov 18 '25	Sale	23.69	4,084	96,754	25,058	Nov 19 06:00 PM
Daly James M	Director	Nov 10 '25	Sale	22.37	30,000	670,983	4,041	Nov 12 06:00 PM
James M Daly	Director	Nov 10 '25	Proposed Sale	22.37	30,000	670,983		Nov 10 05:59 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Sep 15 '25	Sale	23.65	3,498	82,728	43,447	Sep 16 06:00 PM
GAROFALO ELIZABETH A.	Director	Sep 02 '25	Sale	25.98	1,600	41,560	25,382	Sep 03 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Aug 18 '25	Sale	25.18	22,000	554,024	40,130	Aug 19 06:00 PM
Schneyer Mark C.	Officer	Aug 18 '25	Proposed Sale	25.33	22,000	557,260		Aug 18 04:31 PM
Brege Laura	Director	Jun 04 '25	Sale	21.78	14,446	314,634	15,095	Jun 05 06:01 PM
LAURA BREGE	Director	Jun 04 '25	Proposed Sale	21.78	14,446	314,638		Jun 04 04:35 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	May 16 '25	Sale	22.50	4,000	90,000	20,395	May 19 08:52 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	May 16 '25	Sale	25.00	2,000	50,000	62,130	May 19 08:50 PM
Schneyer Mark C.	Officer	May 16 '25	Proposed Sale	17.60	2,000	35,200		May 16 05:10 PM
Kihara James	Officer	May 16 '25	Proposed Sale	17.60	4,000	70,400		May 16 05:06 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	May 02 '25	Sale	14.60	1,327	19,374	23,526	May 02 08:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	May 02 '25	Sale	14.60	3,498	51,071	62,773	May 02 07:59 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Apr 08 '25	Sale	14.82	2,708	40,133	59,456	Apr 08 07:40 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Apr 08 '25	Sale	14.82	1,028	15,235	22,257	Apr 08 07:38 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Mar 26 '25	Sale	17.05	1,095	18,670	21,275	Mar 26 08:10 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Mar 26 '25	Sale	17.05	3,171	54,066	56,889	Mar 26 08:06 PM
GAROFALO ELIZABETH A.	Director	Mar 05 '25	Sale	18.23	4,919	89,673	17,595	Mar 06 06:30 PM
GAROFALO ELIZABETH A.	Director	Mar 05 '25	Proposed Sale	18.23	4,919	89,673		Mar 06 12:17 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Feb 24 '25	Sale	19.96	475	9,481	20,228	Feb 25 06:48 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Feb 24 '25	Sale	19.96	773	15,429	53,882	Feb 25 06:46 PM

PCRX Pacira BioSciences Inc daily Stock Chart

Peers: INCY EXEL ACAD RDUS ENTA CORT ANAB LGND AMLX PBYI

| Held by: IJR VTI VB IWM VBR AVUV VXF SPSM IJT IWN

Index	RUT	P/E	48.71	EPS (ttm)	0.45	Insider Own	3.09%	Shs Outstand	42.97M	Perf Week	5.08%
Market Cap	934.85M	Forward P/E	6.38	EPS next Y	3.41	Insider Trans	-4.79%	Shs Float	41.69M	Perf Month	-5.23%
Enterprise Value	1.11B	PEG	1.01	EPS next Q	0.90	Inst Own	115.73%	Short Float	18.90%	Perf Quarter	-5.81%
Income	21.44M	P/S	1.30	EPS this Y	-7.66%	Inst Trans	-8.93%	Short Ratio	9.18	Perf Half Y	-12.41%
Sales	716.79M	P/B	1.28	EPS next Y	15.32%	ROA	1.52%	Short Interest	7.88M	Perf YTD	-16.04%
Book/sh	16.93	P/C	3.80	EPS next 5Y	6.33%	ROE	2.90%	52W High	27.64 -21.38%	Perf Year	-20.26%
Cash/sh	5.73	P/FCF	7.53	EPS past 3/5Y	- -51.99%	ROIC	1.88%	52W Low	18.80 15.59%	Perf 3Y	-45.61%
Dividend Est.	-	EV/EBITDA	7.64	Sales past 3/5Y	8.98% 10.73%	Gross Margin	71.17%	Volatility	3.44% 4.89%	Perf 5Y	-72.39%
Dividend TTM	-	EV/Sales	1.55	EPS Y/Y TTM	123.74%	Oper. Margin	7.64%	ATR (14)	0.96	Perf 10Y	-61.39%
Dividend Ex-Date	-	Quick Ratio	3.78	Sales Y/Y TTM	3.14%	Profit Margin	2.99%	RSI (14)	50.42	Recom	2.14
Dividend Gr. 3/5Y	- -	Current Ratio	5.26	EPS Q/Q	103.93%	SMA20	5.30%	Beta	0.22	Target Price	29.71
Payout	-	Debt/Eq	0.58	Sales Q/Q	6.49%	SMA50	-6.97%	Rel Volume	0.83	Prev Close	21.24
Employees	790	LT Debt/Eq	0.57	Earnings	Nov 06 AMC	SMA200	-9.79%	Avg Volume	858.89K	Price	21.73
IPO	Feb 03, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.32% -0.88%	Trades		Volume	710,869	Change	2.31%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Barclays	Equal Weight	$27
Nov-17-25	Initiated	H.C. Wainwright	Buy
Jul-25-25	Upgrade	Truist	Hold → Buy	$30
Jan-30-25	Upgrade	Truist	Sell → Hold	$8 → $25
Aug-13-24	Downgrade	Truist	Buy → Sell	$30 → $8
Aug-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$37 → $14
Aug-12-24	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-12-24	Downgrade	Piper Sandler	Overweight → Neutral	$42 → $11
Aug-12-24	Downgrade	JP Morgan	Overweight → Underweight	$45 → $10
Jul-03-24	Downgrade	Barclays	Overweight → Equal Weight	$38 → $25
Mar-07-24	Resumed	JP Morgan	Overweight	$80 → $45
Dec-20-23	Initiated	Raymond James	Outperform	$42
Aug-03-23	Upgrade	TD Cowen	Market Perform → Outperform	$50
Jan-31-23	Resumed	Wedbush	Outperform	$88 → $60
Oct-21-22	Resumed	Jefferies	Buy	$66
Jan-03-22	Resumed	JP Morgan	Overweight	$75 → $83
Jul-26-21	Upgrade	JP Morgan	Neutral → Overweight	$75
Apr-21-21	Resumed	JP Morgan	Neutral	$70
Apr-09-21	Initiated	Berenberg	Buy	$93
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$86

Show Previous Ratings

Feb-09-26 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-03-26 10:00AM	5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates (Zacks)
Jan-28-26 08:00AM	Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors (GlobeNewswire)
Jan-27-26 12:45PM	Pacira (PCRX) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
12:10PM	Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
08:30AM	Loading…
Jan-16-26 08:30AM	Do Options Traders Know Something About Pacira BioSciences Stock We Don't? (Zacks) -7.22%
Jan-14-26 10:18AM	PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific (Zacks)
Jan-13-26 08:00AM	Pacira Announces Agreement with LG Chem to Make EXPAREL Available in Select Asian-Pacific Markets (GlobeNewswire) -5.80%
Jan-12-26 10:14AM	PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates (Zacks)
Jan-08-26 04:01PM	Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues (GlobeNewswire) -9.57%
Jan-07-26 08:00AM	Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences (GlobeNewswire)
Dec-31-25 10:45AM	DOMA intends to nominate three director candidates at Pacira annual meeting (TipRanks)
Dec-30-25 10:41AM	DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc. (PR Newswire)
Dec-18-25 08:00AM	Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care (GlobeNewswire)
Dec-17-25 02:19PM	5 Biotech Stocks to Watch for Potential Upside (Zacks)
02:10PM	Loading…
Dec-16-25 02:10PM	Pacira BioSciences Stock Earns Technical Rating Upgrade (Investor's Business Daily)
Dec-03-25 10:23AM	PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain (Zacks)
08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-02-25 08:00AM	Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera Compared to Radiofrequency Ablation in Chronic Low Back Pain (GlobeNewswire)
Nov-26-25 04:01PM	Pacira BioSciences Files EXPAREL Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical (GlobeNewswire)
Nov-14-25 06:00PM	Bitdeer, Pacira BioSciences, Garrett Motion, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-11-25 08:00AM	Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences (GlobeNewswire)
Nov-10-25 08:09PM	DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business (PR Newswire)
Nov-07-25 12:02AM	Pacira BioSciences Inc (PCRX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-06-25 06:30PM	Pacira (PCRX) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
06:10PM	Pacira (PCRX) Tops Q3 Earnings Estimates (Zacks)
05:06PM	Pacira: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance (GlobeNewswire)
Nov-05-25 08:00AM	Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee (GlobeNewswire)
Nov-04-25 07:00AM	Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control (GlobeNewswire)
10:00AM	Loading…
Oct-30-25 10:00AM	Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline (Zacks)
08:00AM	Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025 (GlobeNewswire)
Oct-29-25 10:00AM	Pacira (PCRX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-28-25 08:00AM	Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee (GlobeNewswire)
Oct-27-25 08:00AM	Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL (GlobeNewswire)
Oct-23-25 08:00AM	Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL (GlobeNewswire)
Oct-21-25 12:10PM	Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
08:30AM	Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL (GlobeNewswire)
Oct-20-25 04:01PM	Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy (GlobeNewswire)
Oct-03-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-15-25 06:04PM	Hanesbrands, Rogers, and More Stocks See Action From Activist Investors (Barrons.com)
Aug-06-25 03:27AM	Pacira BioSciences Inc (PCRX) Q2 2025 Earnings Call Highlights: Strong Growth in EXPAREL Sales ... (GuruFocus.com)
Aug-05-25 08:00PM	Here's What Key Metrics Tell Us About Pacira (PCRX) Q2 Earnings (Zacks)
05:35PM	Pacira (PCRX) Tops Q2 Earnings Estimates (Zacks)
04:35PM	Pacira: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	Pacira BioSciences Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 09:45AM	What To Expect From Pacira BioSciences Inc (PCRX) Q2 2025 Earnings (GuruFocus.com)
Jul-31-25 12:12PM	PharmaCorp Announces Filing of Annual Information Form (GlobeNewswire)
Jul-24-25 08:00AM	Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025 (GlobeNewswire)
Jul-22-25 08:00AM	Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts (GlobeNewswire)
Jul-16-25 08:40AM	Investors who lost money with shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation in connection with Lawsuit (PR Newswire)
Jul-10-25 11:41AM	Pacira BioSciences Gene Therapy Shows Sustained Knee Osteoarthritis Improvement (Insider Monkey)
Jul-03-25 04:01PM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-18-25 11:06AM	Is the Options Market Predicting a Spike in Pacira BioSciences Stock? (Zacks)
08:00AM	Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient's Journey to Pain Relief and Innovation in Care at BIO 2025 (GlobeNewswire)
Jun-11-25 08:00AM	Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee (GlobeNewswire)
Jun-05-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-25 02:02PM	PharmaCorp Rx Inc. Reports First Quarter 2025 Results and Announces Non-Binding Letters of Intent to Acquire Four Pharmacies (GlobeNewswire)
May-15-25 08:00AM	Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee (GlobeNewswire)
May-14-25 08:00AM	Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences (GlobeNewswire)
May-13-25 10:35AM	Lawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation (PR Newswire) -6.74%
May-09-25 11:12AM	Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates (Zacks)
03:41AM	Pacira BioSciences Inc (PCRX) Q1 2025 Earnings Call Highlights: Strong EXPAREL Sales and ... (GuruFocus.com)
May-08-25 05:30PM	Pacira (PCRX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Pacira (PCRX) Q1 Earnings Surpass Estimates (Zacks)
04:11PM	Pacira: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Pacira BioSciences Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 05:20PM	Pacira BioSciences Q1 2025 Earnings Preview (Seeking Alpha)
10:20AM	Pacira BioSciences Inc (PCRX) Q1 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
May-06-25 06:05PM	Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis (GlobeNewswire)
May-05-25 09:13AM	5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates (Zacks)
May-02-25 08:00AM	Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis (GlobeNewswire)
May-01-25 05:10PM	Amgen (AMGN) Tops Q1 Earnings and Revenue Estimates (Zacks)
10:01AM	ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
09:34AM	IQVIA Gears Up to Report Q1 Earnings: What's in Store for the Stock? (Zacks)
08:32AM	Pharmacorp Completes Acquisition of Pre-1954 Charter Company in Ontario (GlobeNewswire)
Apr-29-25 10:01AM	Analysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
08:00AM	Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025 (GlobeNewswire)
Apr-28-25 08:00AM	Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee (GlobeNewswire) +5.52%
Apr-22-25 04:01PM	Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee (GlobeNewswire)
Apr-21-25 12:10PM	Why Pacira (PCRX) is Poised to Beat Earnings Estimates Again (Zacks) +5.07%
08:15AM	DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders (PR Newswire)
Apr-17-25 05:00PM	Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders (GlobeNewswire)
Apr-15-25 01:45PM	Is Pacira BioSciences, Inc. (PCRX) the Best Pharma Stock to Buy for Long Term Growth? (Insider Monkey)
Apr-11-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-10-25 05:00AM	The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb (Zacks) -8.32%
Apr-09-25 01:45PM	Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More (Zacks)
10:03AM	Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act (Seeking Alpha)
09:41AM	Pacira price target raised to $28 from $25 at Truist (TipRanks)
05:53AM	Pacira (PCRX) Surges 14.7%: Is This an Indication of Further Gains? (Zacks)
Apr-08-25 11:29AM	PCRX Stock Soars on Exparel Patent Settlement With Generic Players (Zacks) +14.67%
Apr-07-25 04:30PM	Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL (GlobeNewswire)
Apr-04-25 11:30AM	Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report? (Zacks)
09:37AM	PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study (Zacks)
Apr-03-25 08:00AM	Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee (GlobeNewswire)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)
08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RIKER LAUREN	Senior Vice President, Finance	Feb 02 '26	Sale	20.81	4,000	83,240	52,313	Feb 03 06:24 PM
WILLIAMS KRISTEN	Chief Administrative Officer	Feb 02 '26	Sale	20.53	13,137	269,703	131,303	Feb 03 06:24 PM
RIKER LAUREN	Officer	Feb 02 '26	Proposed Sale	21.05	4,000	84,219		Feb 02 04:12 PM
WILLIAMS KRISTEN	Officer	Feb 02 '26	Proposed Sale	20.53	13,137	269,703		Feb 02 10:55 AM
RIKER LAUREN	Senior Vice President, Finance	Jan 05 '26	Sale	24.24	1,416	34,324	59,064	Jan 06 05:30 PM
RIKER LAUREN	Officer	Jan 05 '26	Proposed Sale	24.24	1,416	34,324		Jan 05 11:22 AM
Cross Shawn	Chief Financial Officer	Dec 09 '25	Option Exercise	16.45	15,896	261,489	72,146	Dec 11 09:47 PM
Cross Shawn	Chief Financial Officer	Dec 10 '25	Option Exercise	16.45	9,104	149,761	65,354	Dec 11 09:47 PM
Cross Shawn	Chief Financial Officer	Dec 09 '25	Sale	25.03	15,896	397,877	56,250	Dec 11 09:47 PM
Cross Shawn	Chief Financial Officer	Dec 10 '25	Sale	25.14	9,104	228,875	56,250	Dec 11 09:47 PM
Cross Shawn	Officer	Dec 10 '25	Proposed Sale	25.14	9,104	228,912		Dec 10 04:41 PM
Cross Shawn	Officer	Dec 09 '25	Proposed Sale	25.03	15,896	397,837		Dec 09 04:31 PM
SLONIN JONATHAN	Chief Medical Officer	Nov 17 '25	Sale	24.09	3,960	95,396	178,367	Nov 19 04:32 PM
SLONIN JONATHAN	Officer	Nov 17 '25	Proposed Sale	24.09	3,960	95,396		Nov 17 10:25 AM
Cross Shawn	Chief Financial Officer	Nov 10 '25	Sale	22.09	12,060	266,405	56,250	Nov 13 04:13 PM
Cross Shawn	Officer	Nov 10 '25	Proposed Sale	22.09	12,060	266,405		Nov 10 10:02 AM
Ceesay Abraham	Director	Sep 04 '25	Sale	27.19	2,354	64,005	9,039	Sep 08 05:37 PM
Ceesay Abraham	Director	Sep 04 '25	Proposed Sale	27.19	2,354	64,005		Sep 04 09:40 AM
BIGAL MARCELO	Director	Aug 07 '25	Sale	23.67	4,912	116,267	11,393	Aug 11 04:09 PM
BIGAL MARCELO	Director	Aug 07 '25	Proposed Sale	23.67	4,912	116,279		Aug 07 03:17 PM
RIKER LAUREN	Senior Vice President, Finance	Jun 04 '25	Sale	26.21	5,578	146,208	59,564	Jun 05 05:40 PM
WILLIAMS KRISTEN	Chief Administrative Officer	Jun 04 '25	Sale	26.24	14,376	377,226	161,574	Jun 05 05:37 PM
RIKER LAUREN	Officer	Jun 04 '25	Proposed Sale	26.21	5,579	146,209		Jun 04 11:36 AM
WILLIAMS KRISTEN	Officer	Jun 04 '25	Proposed Sale	26.24	14,376	377,226		Jun 04 10:37 AM
GAUGLER DARYL	Officer	Mar 06 '25	Proposed Sale	23.25	500	11,625		Mar 06 12:06 PM

MIRM

Mirum Pharmaceuticals Inc

ACAD

Acadia Pharmaceuticals Inc

PCRX

Pacira BioSciences Inc

Upgrade your FINVIZ experience